



**ContextVision**

## CONTEXTVISION AB THIRD QUARTER 2017

### Q3 HIGHLIGHTS

- Stable overall sales
- Platform for product development established
- Encouraging results from feasibility study in lung cancer

### Q3 FINANCIAL DATA

- Sales of 18.0 MSEK (20.3)
- Operating result of -0.1 MSEK (2.0) and operating margin of -0.7% (9.6%)
- Research costs of 4.0 MSEK (4.7)
- Earnings per share of -0.1 (0.2) SEK



## THIRD QUARTER 2017

ANITA TOLLSTADIUS, THE COMPANY'S CEO COMMENTED:

*Development of our first product for the evaluation of prostate cancer via digital pathology is underway according to plan, and will be ready for market by the end of 2018. We also saw stable sales within our present business area.*

We continue to broaden our research and product development within our new business area – digital pathology – while also supporting current customers to ensure stable sales. In addition, we have invested in infrastructure that will facilitate effective development of a product portfolio.

Over the last year, we have proven our skills within deep learning. This is very important for the development of highly-accurate algorithms, but creating clinically-valuable decision support tools demands much more than that. We are aware that other research groups are involved in developing new algorithms for the detection of cancer in digital pathology images. ContextVision is therefore taking it a step further and focusing on developing a product that delivers value in a clinical situation. The development of our first product is running well and we are ready for the next phase, which will include preliminary training and a product framework.

We spent a significant amount of effort and resources in creating a robust platform for product development, which is now complete and simplifies the R&D process for digital pathology on a broader basis. Today, we not only have the technical expertise in place, but also the tools for handling large amounts of images, the tools needed for effective development of deep learning algorithms, and a unique method for objective annotation of digital pathology images. Special tools are required to classify different patterns in order to train the algorithms properly and we have set up a lab with SciLife labs in Uppsala to create objective ground truth data. Objective data are crucial for the successful advancement of digital pathology.

In order to progress toward a broader product portfolio, we have expanded our network of national and international contacts and have performed feasibility studies on other forms of cancer. With this, we have achieved very encouraging results applying

deep learning to a data set from lung cancer patients. However, today's manual assessment is highly subjective and studies have shown that there is a significant inter- and intra-individual variation dependent upon each pathologist's individual competence, experience and skill. This indicates that diagnoses may be incomplete or even inaccurate. At the same time, demand in cancer diagnostics is constantly increasing as new therapy options and treatment modalities in clinical oncology require more detailed, time consuming diagnoses.

In October, the Digital Pathology Association (DPA) held a meeting in San Diego that included both pathologists and representatives from the industry. Following the first FDA clearance to market a scanner for primary diagnostic use in the U.S., there was an increased optimism about the market development and an even stronger interest in image analysis. People are aware that humans are not so good at quantification of images and new studies show that a lot of time and money can be saved when using automated analysis for image quantification. This has encouraged us further.

We continue to strengthen our team and broaden our international network by recruiting new key team members and we expect to continue growth. In order to host our team and enhance our creativity, we started developing our facilities in Linköping, where R&D is based.

Although developing our new business area is important, we continue to serve our present customers within medical imaging and further develop our present portfolio. We intend to remain market leaders in image enhancement and invest in research for new opportunities.

Sales during the third quarter reached 18,0 MSEK which was 12% lower than third quarter 2016. This was expected as we had a large order for a field upgrade this time last year. Overall, sales are stable and we continue to generate the majority of our sales from the ultrasound portfolio.

Our total research cost was 4,0 MSEK this quarter, the majority of which is related to digital pathology. The lower cost level compared to the second quarter reflects the vacation period and it is our intention to continue our investments in research both within this field and within medical imaging.

In conclusion, the third quarter was a very good quarter for digital pathology development and we continue with our strategies and move towards our objectives at a very good pace. We have secured collaborations and built infrastructure to enable effective development of our first product and, during this quarter, we established a platform for the development of a broader product portfolio.

## THIRD QUARTER 2017

### NET SALES AND OPERATING PROFIT

#### NET SALES

- The sales in the third quarter 2017 ended at 18.0 MSEK, which represents a decrease of 11% compared to the third quarter 2016, when ContextVisions sales amounted to 20.3 MSEK.
- The currency exchange rates had an average effect on sales of 1.6% during the quarter. Most of the effect originated in changes in the JPY exchange rates, while the EUR and USD exchange rates had smaller effects during the quarter.

#### OPERATING PROFIT AND MARGIN

- ContextVisions operating result for the third quarter was -0.1 MSEK (2.0), and the operating margin -0.7% (9.6%).
- The cost for research within new areas (not capitalized) ended at 4.0 MSEK (4.7) during Q3.
- Capitalization is recorded as intangible fixed assets only when product development meets certain requirements. Capitalized costs for development of one product (total 0.1 MSEK) has been recorded during the quarter. This is in line with the level of capitalization compared to previous year, when the capitalization in the same quarter was 0.3 MSEK.
- The external costs as well as the personnel costs for the quarter are both in line with the same quarter previous year.

#### CASH-FLOW AND FINANCING

- Cash flow for the third quarter represented a positive change of 5.0 MSEK (0.4).
- Cash amounted to 42.8 MSEK (39.0) at period end.
- Equity at period end amounted to 57.8 MSEK (59.0) giving an equity ratio of 76.9% (78.9%).

### GOVERNMENT GRANT

- ContextVision was awarded a EU grant in 2015, together with its academic partner University of Applied Sciences an Arts Western Switzerland (HES-SO).
- The company's total part of the grant is TEUR 404, and it will be paid out during a three-year period.
- The first part of the grant (0.6 MSEK) was received in Q4 2015.
- The second part of the grant (1.3 MSEK) was received in Q4 2016, and was recorded as a cost decrease.
- The grant for 2017 is expected to be received in Q4, and will then be recorded as a cost decrease. The grant has therefore not been recorded in the P&L statement and has not affected the results for Q3.

### EMPLOYEES AND MANAGEMENT

- At period end the company had 42 (42) employees of which 22 (21) are dedicated to research and development. 2 employees are located in the USA and 1 in China.

### CONTEXTVISION GROUP

- The group consists of ContextVision AB (publ), company registration number 556377-8900 as the parent company, and ContextVision Inc Corp registration number 36-4333625 State of Illinois, USA, as the wholly owned subsidiary.
- Operations in the group are conducted primarily in the parent company and consist of research and development, sales, marketing and administrative functions.

### RISKS & UNCERTAINTIES

- ContextVision's major risk factors include business risks connected to the general global financial situation, to the level of healthcare investment on different markets, currency exchange risks, the company's ability to recruit and keep qualified

employees and the effect of political decisions.

- The company's risk factors are described in the annual report 2016. The risks and uncertainties have not changed significantly since then.
- This quarterly report provides a fair and true overview of the company's and the Group's activities, position and results, and describes the risks and uncertainties of significance faced by ContextVision and by the companies in the Group.

## SUBSEQUENT EVENTS

- No significant events have occurred during the period between period-end and date of issuance of this report.

The Board of Directors of ContextVision AB  
Stockholm 2017-10-25

*This report has not been reviewed by the company's auditors.*

## PRESENTATION AND REPORTING DATES

This quarterly report will be published on the company's website on the 26<sup>th</sup> of October, 2017.

There will be a video presentation released on the 27<sup>th</sup> of October, at 09.00 CET.

Please follow the link:

<http://webtv.nu/contextvisionq32017>

Please visit [www.contextvision.com](http://www.contextvision.com) for further information, or use [shareholderinfo@contextvision.se](mailto:shareholderinfo@contextvision.se) to send a question directly to management.

### REPORTING DATES

Q4 and annual result 2016	February 23, 2017
---------------------------	-------------------

Annual report available	April 6, 2017
-------------------------	---------------

Q1 result 2017	April 27, 2017
----------------	----------------

Annual General Meeting	May 10, 2017
------------------------	--------------

Q2 result 2017	August 17, 2017
----------------	-----------------

Q3 result 2017	October 26, 2017
----------------	------------------

Q4 and 12 months 2017	February 22, 2018
-----------------------	-------------------

### FOR MORE INFORMATION PLEASE CONTACT:

Anita Tollstadius, CEO  
Phone +46 (0)8 750 35 50

## CONTEXTVISION FAST FACTS

- ContextVision is a spin-off from the Image Processing Laboratory at Linköping University, Sweden. The corporate identity was established in 1983 with the first OEM agreement in radiology in 1987. ContextVision is traded on the Oslo Stock Exchange since 1997.
- ContextVision has a specialist competence within medical image processing and artificial intelligence technologies.
- A world leader in image enhancement using proprietary technology based on GOP.
- ContextVision has entered into a new progressive phase to become a leader within new technologies, such as deep learning.
- The Company is running a research program to take a leading position on the new, fast growing digital pathology market.

### THE COMPANY OFFERS:

- 30 years of successful experience in OEM business.
- Unprecedented image enhancement for ultrasound, X-Ray, MRI, CT, mammography and iRV.
- Long standing corporate commitment to R&D that ensures timely and rewarding upgrade paths.
- Strong customer relationships to ensure their success.
- Expert training in image processing for our customers.
- Compatibility across different image formats and major computer platforms.
- ContextVision's technology enables the company's customers to provide superior digital imaging solutions for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users.

**CONSOLIDATED INCOME STATEMENT (SEK 1000)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Net sales	18 036	20 334	58 041	57 055	81 917
<b>Total revenues</b>	<b>18 036</b>	<b>20 334</b>	<b>58 041</b>	<b>57 055</b>	<b>81 917</b>
Goods for resale	-476	-569	-1 410	-1 490	-2 448
Other external costs	-5 373	-5 266	-19 901	-14 923	-23 369
Personnel costs	-11 248	-11 213	-36 318	-34 315	-45 507
Depreciation assets	-1 057	-1 325	-3 759	-3 491	-4 824
<b>Operating results</b>	<b>-119</b>	<b>1 961</b>	<b>-3 348</b>	<b>2 836</b>	<b>5 769</b>
Interest income	-	1	-	-	-
Interest cost	-	-	-10	-2	-2
<b>Results after financial items</b>	<b>-119</b>	<b>1 962</b>	<b>-3 358</b>	<b>2 833</b>	<b>5 767</b>
Tax	-708	-461	-33	-685	-1 514
<b>Net results</b>	<b>-827</b>	<b>1 501</b>	<b>-3 391</b>	<b>2 147</b>	<b>4 253</b>
Earnings per share after tax (SEK)	-0,11	0,19	-0,44	0,28	0,55

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Effect of currency hedging	-84	-2	-66	-195	-24
Translation difference	-65	29	-175	56	161
<b>Total other comprehensive income</b>	<b>-149</b>	<b>27</b>	<b>-241</b>	<b>-139</b>	<b>137</b>
Net result for the period	-827	1 501	-3 391	2 147	4 253
<b>Total comprehensive income for the period</b>	<b>-976</b>	<b>1 528</b>	<b>-3 632</b>	<b>2 008</b>	<b>4 390</b>

**FINANCIAL HIGHLIGHTS**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Earnings per share after tax (SEK) before/after dilution	-0,11	0,19	-0,44	0,28	0,55
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	-0,7	9,6	-5,8	5,0	7,0
Solidity (per cent)	76,9	78,9	76,9	78,9	77,5

**DEFINITIONS**

*Operating margin: Operating income excluding non-recurring items as a percentage of net sales.*

*Profit margin: Result after financial items as a percentage of net sales.*

*Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.*

*Solidity (Equity ratio): Equity as a percentage of total assets.*

## SALES BY REGION (MSEK)

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Asia	10,4	11,2	30,0	29,2	42,6
Europe	6,3	6,5	20,7	19,5	28,6
USA	1,3	2,6	7,3	8,3	10,7
<b>Total</b>	<b>18,0</b>	<b>20,3</b>	<b>58,0</b>	<b>57,0</b>	<b>81,9</b>

## SALES BY PRODUCT (MSEK)

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
XR	1,8	2,7	7,9	7,4	10,0
US 2D	11,3	11,1	33,6	32,1	47,9
US 3D	2,8	2,4	9,1	7,4	11,4
MR	1,9	3,6	5,6	8,7	10,5
Others (iRV, CT, Mammo)	0,2	0,5	1,8	1,4	2,1
<b>Total</b>	<b>18,0</b>	<b>20,3</b>	<b>58,0</b>	<b>57,0</b>	<b>81,9</b>

## CONSOLIDATED BALANCE SHEET (SEK 1000)

	Q3, 2017	Q3 2016		FULL YEAR 2016
Intangible fixed assets	11 700	15 725		14 628
Tangible assets	530	525		527
Other financial assets	323	323		323
Inventories	702	267		294
Current receivables	19 125	19 079		20 616
Cash and bank	42 815	38 963		42 910
<b>Total assets</b>	<b>75 195</b>	<b>74 883</b>		<b>79 299</b>
Equity	57 793	59 045		61 426
Deferred taxes	1 509	1 105		1 508
Current liabilities	15 893	14 733		16 365
<b>Total equity and liabilities</b>	<b>75 195</b>	<b>74 883</b>		<b>79 299</b>

## CHANGE IN EQUITY (SEK 1000)

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Opening balance	58 770	57 517	61 426	57 036	57 036
Total comprehensive income for the period	-976	1 528	-3 632	2 008	4 390
<b>Closing balance</b>	<b>57 793</b>	<b>59 045</b>	<b>57 793</b>	<b>59 045</b>	<b>61 426</b>



**CONSOLIDATED STATEMENT OF CASH FLOWS (SEK 1000)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Result after financial items	-119	1 962	-3 358	2 833	5 767
Depreciation and write-down of assets	945	1 325	3 866	3 491	6 164
Unrealized gain/loss on current investments	-84	-2	-66	-195	-24
Income tax paid	492	-1 342	-3 284	-3 325	-1 399
<b>Cash flow from operating activities</b> before change in working capital	<b>1 234</b>	<b>1 943</b>	<b>-2 842</b>	<b>2 804</b>	<b>10 508</b>
<b>Change in working capital</b>					
Increase (-)/decrease (+) inventories	-48	319	-408	129	102
Increase (-)/decrease (+) current receivables	3 770	34	4 363	2 237	-3 448
Increase (+)/decrease (-) liabilities	118	-1 586	-158	101	2 365
<b>Cash flow from operating activities</b>	<b>5 074</b>	<b>710</b>	<b>955</b>	<b>5 269</b>	<b>9 527</b>
<b>Investing activities</b>					
Investments in intangible assets	-69	-260	-884	-1 719	-1 976
Investments in tangible assets	-	-	-167	-161	-215
Other financial assets	5	-69	-	-69	-69
<b>Cash flow from investing activities</b>	<b>-64</b>	<b>-329</b>	<b>-1 051</b>	<b>-1 949</b>	<b>-2 260</b>
Financing activities					
Cash flow from financing activities	0	0	0	0	0
<b>Cash flow for the period</b>	<b>5 010</b>	<b>381</b>	<b>-95</b>	<b>3 320</b>	<b>7 266</b>
Change of liquid assets					
Liquid assets at beginning of period	37 805	38 582	42 910	35 644	35 644
<b>Liquid assets at period end</b>	<b>42 815</b>	<b>38 963</b>	<b>42 815</b>	<b>38 963</b>	<b>42 910</b>

## PARENT COMPANY INCOME STATEMENT (SEK 1000)

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Net sales	18 036	20 334	58 041	57 055	81 917
<b>Total revenues</b>	<b>18 036</b>	<b>20 334</b>	<b>58 041</b>	<b>57 055</b>	<b>81 917</b>
Goods for resale	-476	-569	-1 410	-1 490	-2 448
Other external costs	-6 172	-6 107	-22 624	-17 394	-26 715
Personnel costs	-10 498	-10 437	-33 765	-32 004	-42 374
Depreciation assets	-1 057	-1 325	-3 759	-3 491	-4 824
<b>Operating results</b>	<b>-168</b>	<b>1 896</b>	<b>-3 518</b>	<b>2 676</b>	<b>5 556</b>
Interest income	-	1	-	-	-
Interest cost	-	-	-10	-4	-2
Dividends from group company	-	-	-	-	275
<b>Results after financial items</b>	<b>-168</b>	<b>1 897</b>	<b>-3 528</b>	<b>2 673</b>	<b>5 829</b>
Provision for tax allocation reserve	-	-	-	-	-1 500
Tax	-691	-445	-22	-668	-985
<b>Net results</b>	<b>-859</b>	<b>1 452</b>	<b>-3 550</b>	<b>-2 005</b>	<b>3 344</b>
Earnings per share after tax (SEK)	-0,11	0,19	-0,46	0,26	0,43

## PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Effect of currency hedging	-84	-2	-66	-195	-24
<b>Total other comprehensive income</b>	<b>-84</b>	<b>-2</b>	<b>-66</b>	<b>-195</b>	<b>-24</b>
Net result for the period	-859	1 452	-3 550	2 005	3 344
<b>Total comprehensive income for the period</b>	<b>-943</b>	<b>1 450</b>	<b>-3 616</b>	<b>1 810</b>	<b>3 320</b>

## FINANCIAL HIGHLIGHTS

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Earnings per share after tax (SEK) before/after dilution	-0,11	0,19	-0,46	0,26	0,43
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	-0,9	9,3	-6,1	4,7	6,8
Solidity (per cent)	68,4	71,5	68,4	71,5	69,4

## DEFINITIONS

*Operating margin: Operating income excluding non-recurring items as a percentage of net sales.*

*Profit margin: Result after financial items as a percentage of net sales.*

*Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.*

*Solidity (Equity ratio): Equity as a percentage of total assets.*

**SALES BY REGION (MSEK)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Asia	10,4	11,2	30,0	29,2	42,6
Europe	6,3	6,5	20,7	19,5	28,6
USA	1,3	2,6	7,3	8,3	10,7
<b>Total</b>	<b>18,0</b>	<b>20,3</b>	<b>58,0</b>	<b>57,0</b>	<b>81,9</b>

**SALES BY PRODUCT (MSEK)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
XR	1,8	2,7	7,9	7,4	10,0
US 2D	11,3	11,1	33,6	32,1	47,9
US 3D	2,8	2,4	9,1	7,4	11,4
MR	1,9	3,6	5,6	8,7	10,5
Others (iRV, CT, Mammo)	0,2	0,5	1,8	1,4	2,1
<b>Total</b>	<b>18,0</b>	<b>20,3</b>	<b>58,0</b>	<b>57,0</b>	<b>81,9</b>

**PARENT COMPANY BALANCE SHEET (SEK 1000)**

	Q3 2017	Q3 2016			FULL YEAR 2016
Intangible fixed assets	11 700	15 725			14 628
Tangible assets	530	525			527
Other financial assets	540	540			540
Inventories	702	268			294
Current receivables	19 081	19 037			20 571
Cash and bank	42 349	38 540			42 501
<b>Total assets</b>	<b>74 902</b>	<b>74 635</b>			<b>79 061</b>
Equity	51 246	53 352			54 862
Untaxed reserves	6 774	5 200			6 773
Current liabilities	16 882	16 083			17 426
<b>Total equity and liabilities</b>	<b>74 902</b>	<b>74 635</b>			<b>79 061</b>

**CHANGE IN EQUITY (SEK 1000)**

	Q3 2017	Q3 2016	NINE MONTHS 2017	NINE MONTHS 2016	FULL YEAR 2016
Opening balance	52 189	51 902	54 862	51 542	51 542
Total comprehensive income for the period	-943	1 450	-3 616	1 810	3 320
<b>Closing balance</b>	<b>51 246</b>	<b>53 352</b>	<b>51 246</b>	<b>53 352</b>	<b>54 862</b>

**BASIS OF PREPARATION**

The interim condensed consolidated financial statements for the 3:rd quarter ended September 30, 2017 have been prepared in accordance with IAS 34 Interim Financial Reporting and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as of December 31, 2016. There has been no changes in the accounting principles or methods for calculation during the period.

## GLOSSARY

### ARTIFICIAL INTELLIGENCE (AI)

Artificial Intelligence is the intelligence exhibited by machines or software.

### DEEP LEARNING

Deep learning is the latest very powerful technology within machine learning; machine learning with deep neural networks

### DIGITAL PATHOLOGY

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

### GOP® (GENERAL OPERATOR PROCESSOR)

ContextVision's methodology and technology base for image analysis and image enhancement, detecting structures in an image and relating them to their wider context in order to increase visualization accuracy.

### GOPICE® (IMAGE CUBICLE ENHANCEMENT)

ContextVision's real-time 3D volumetric image enhancement product, for OEM embedded software.

### GOPVIEW® / PLUSVIEW®

The family names for ContextVision's 2D product lines of OEM-embedded software.

### IMAGE ANALYSIS

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

### IMAGE PROCESSING

A generic term used to describe the computation of digital images, typically to enhance or analyze them.

### IMAGE ENHANCEMENT

To improve the visual quality of a digital image by increasing the visibility of relevant structures, as in edge/contrast enhancement and the suppression of noise or artifacts.

### MACHINE LEARNING

Machine learning is the study of computer algorithms that improve automatically through experience

### MAMMOGRAPHY

An X-ray method used to examine the human breast.

### MODALITY

A device that generates internal images of the body, such as X-ray, ultrasound, magnetic resonance imaging, and computed tomography.

### MRI (MAGNETIC RESONANCE IMAGING)

A non-invasive procedure, generated by variations in strong magnetic fields, that produces a two-dimensional view of an internal organ or structure, especially the brain and spinal cord.

### OEM

The acronym for Original Equipment Manufacturer.

### REALICE™

REALiCE is a volume enhancement and rendering product package for 3D and 4D fetal volume visualization.

### US (ULTRASOUND)

A procedure in which high-energy sound waves are bounced off internal tissues or organs to create echoes. The echo patterns are displayed on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.

### XR (X-RAY)

A diagnostic device in which radiation is used to create images for examination of soft and hard tissue, such as muscle and bone.



ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision has decided to take a lead position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing heavily in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D Ultrasound, MRI, X-Ray and Mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV.



FOR MORE INFORMATION, PLEASE VISIT [WWW.CONTEXTVISION.COM](http://WWW.CONTEXTVISION.COM)